Title:Current Remedial Strategies for the Treatment of Rheumatoid Arthritis
through the Oral Route with Janus Kinase Inhibitors
Volume: 13
Issue: 1
Author(s): Pooja Mathur, Ravinder Verma, Manish Kumar, Vikas Jhawat, Rohit Dutt and Shailendra Bhatt*
Affiliation:
- School of Medical and Allied Sciences, GD Goenka University, Gurugram, Haryana, India
Keywords:
Rheumatoid, arthritis, jakinibs, cytokinins, JAK-STAT pathway, DMARDs.
Abstract:
Rheumatoid arthritis (RA) is a well-known chronic inflammatory disease that results in
articular degradation, comorbidities, and body part functional loss. In the last two decades, the development
of effective biologics and small compounds, such as Janus kinase inhibitors (Jakinibs),
has significantly improved clinical outcomes. Low-molecular-weight chemicals known as jakinibs
are currently used for effective treatment of RA. Jakinibs are a new class of drugs being developed
to treat RA, and several of them are now in different phases of clinical trials to establish their safety
and efficacy in humans. Jakinibs can be very different in their selectivity against JAK inhibitors.
For an efficient therapy of RA, it is critical to fully comprehend the properties of JAK inhibitors as
well as their mechanism of action. Tofacitinib, Baricitinib, Upadacitinib, Peficitinib, Filgotinib, Decernotinib,
Itacitinib, Ruxolitinib, and PF-06651600 are a few selective orally active Jakinibs that
have entered clinical trials to treat RA. This review aims to elaborate on Jakinibs for the treatment
of Rheumatoid Arthritis (RH), including their mechanism of action (MOA), efficacy and safety profiles,
clinical trials of adverse effects (AEs) associated with Jakinibs and combination therapy with
other DMARDs.
